Lanthio Pharma is a privately held drug discovery company that applies its proprietary lanthionine-peptide drug discovery technology LanthioPepTM for the generation of novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity. Lanthio Pharma has generated stable, peptidase-resistant lanthionine peptides with highly specific agonistic activity for a number of GPCR targets, which is a focus area of the company.
Funding Rounds (2) - $11.12MUpdate
|May 13, 2015||genengnews.com - MorphoSys Acquires Lanthio Pharma|
|May 21, 2014||Business Wire - Lanthio Pharma receives Dutch Government loan of up to €3.6 million to develop novel therapy for lung fibrosis|
|Nov 28, 2012||FinSMEs - Lanthio Pharma raises 6187680 in venture round|
9747 AG Groningen